drugset / Trial / NCT07689604
META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
Phase 0
Not yet recruiting
18 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Hangzhou Leman Biotech Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
A Study of Metabolically Armed Autologous CD19 CAR T-Cell Therapy (META 10-19) in Patients with Relapsed/Refractory Autoimmune Hemolytic Anemia
Timeline
- Start
- 2026-07-08
- Primary completion
- 2027-05-01
- Completion
- 2028-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | META 10-19 | Cell therapy | — | Intravenous |